Kisspeptin-10 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Kisspeptin-10 for Health & Longevity

Created on 07/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Kisspeptin-10 is a natural brain peptide sitting atop the reproductive hormone system. Its best-supported effect is a rapid, reliable rise in reproductive hormones, and it can heighten brain responses tied to arousal. Longevity benefit remains unproven. It is unapproved and experimental, relying on unregulated supply; long-term safety and repeated dosing stay open questions. (Full Review)

Protocol

Route
Injection (IV or subcutaneous)
Intranasal delivery recently shown to raise gonadotropins rapidly
Dosing Pattern
Intermittent / pulsatile
Mimics natural rhythm and preserves responsiveness; continuous exposure risks desensitization
Dosing Frequency
Repeated or infused, not single daily
Very short half-life (minutes) means a single bolus produces only a brief pulse
Time to effect
Hormone Rise (LH)
Minutes to ~1 hour
Reproductive hormone increase occurs shortly after administration
Sexual Brain Processing
Acute (during infusion)
Arousal-related brain effects observed acutely in trials
Cumulative Benefit
None evidenced
No evidence base for benefits building over weeks

Benefits

Contraindications
  • Hormone-sensitive cancers (e.g., prostate, certain breast cancers)
  • Pregnancy or breastfeeding
  • Active fertility treatment without specialist supervision
  • Unable to verify product identity, sterility, and purity
    •
Key Interactions
  • GnRH agonists and antagonists (e.g., leuprolide, cetrorelix)
  • Sex-hormone therapies
  • Reproductive-axis peptides (gonadorelin/GnRH analogs, hCG, PT-141)
  • Testosterone replacement therapy
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: Unknown long-term safety and absence of regulatory approval; product quality, purity, and contamination risk
    •
  • Low: Injection-site and administration reactions; transient hormonal and physiological effects
    •
  • Speculative: Receptor desensitization with sustained high dosing; effects on hormone-sensitive conditions
    •

Monitoring

Marker Target Why
Luteinizing Hormone (LH) Men ~1.5–9 IU/L; women varies by cycle phase Direct readout of kisspeptin's primary action on the axis
Follicle-Stimulating Hormone (FSH) Men ~1.5–12 IU/L; women varies by cycle phase Second pituitary hormone driven by the axis
Total Testosterone (men) ~500–900 ng/dL Key downstream hormone reflecting axis stimulation in men
Free Testosterone (men) ~15–25 pg/mL Bioavailable fraction, often more informative than total
Estradiol (women) Cycle-phase dependent Key downstream hormone reflecting axis stimulation in women
Fasting Glucose / Fasting Insulin Glucose ~70–85 mg/dL; insulin <8 µIU/mL Screens the exploratory metabolic/insulin interaction

Cadence: Baseline, then ~4–6 weeks after starting or any change in use, then every 3–6 months if use continues

Qualitative Assessment

  • Libido and subjective sexual desire or arousal
  • Mood and emotional well-being
  • Energy and general vitality
  • Any menstrual-cycle changes in women
  • Any injection-site reactions or signs of infection
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.